Clinical Trials Browser

Phase 3 × Waldenstrom Macroglobulinemia × Bortezomib × Clear all

NCT01788020 2024-05-13

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Phase 3 Completed

Waldenstrom Macroglobulinemia, Neoplasms